8 citations
,
August 2022 in “Pharmaceutics” Erythrocyte-anchored nanoparticles improved Cepharanthine delivery and effectiveness for treating acute lung injury.
83 citations
,
April 1992 in “Journal of Biological Chemistry” Four-amino acid part makes enzyme sensitive to finasteride.
October 2024 in “Iraqi postgraduate medical journal” Ciprofloxacin is slightly more effective than Clindamycin for reducing acne.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
December 2025 in “JGH Open” Early diagnosis and treatment with corticosteroids can improve outcomes in Cronkhite–Canada syndrome.
75 citations
,
August 2005 in “Expert Opinion on Pharmacotherapy” Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.
70 citations
,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
January 2007 in “日本看護学会抄録集 成人看護1” Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.
1 citations
,
January 2020 Cepharanthine shows promise as a potential lung cancer treatment by effectively killing cancer cells.
May 2024 in “International journal of medicine and psychology.” Ticagrelor works better than clopidogrel in reducing platelet activity in elderly patients with acute coronary syndrome.
42 citations
,
January 2008 in “Clinical colorectal cancer” Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.
April 2021 in “Anatolian current medical journal :” A patient developed hair loss after hepatitis C treatment with sofosbuvir and ribavirin.
12 citations
,
June 2019 in “Psychoneuroendocrinology” Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
14 citations
,
April 2022 in “Molecules” Pulmonary delivery of cepharanthine significantly improves its effectiveness and shows promise for treating lung fibrosis linked to COVID-19.
August 2013 in “Gastroenterology” A 60-year-old man with Cronkhite-Canada syndrome improved with treatment, but the condition has a high mortality rate and a risk of colorectal cancer.
6 citations
,
September 2002 in “Acta pædiatrica” A cystic fibrosis patient developed Cushing's syndrome from a drug interaction between itraconazole and inhaled budesonide.
5 citations
,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
48 citations
,
February 2006 in “Molecular and Cellular Endocrinology” 5α-reductase inhibitors may reduce male fertility and could be used for male contraception.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
April 2023 in “Journal of Investigative Dermatology” Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
22 citations
,
March 1999 in “International Journal of Clinical Practice” Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
64 citations
,
March 2008 in “Neuropsychopharmacology”
1 citations
,
July 2024 in “The International Journal of Medical Science and Health Research” 5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
147 citations
,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
December 2015 in “Vascular Pharmacology” Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.